Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA User Fee Review Staff Hiring To Be Lower Than Projected Under PDUFA III

Executive Summary

FDA plans to add 376 additional staff years to the drug review process over the course of PDUFA III, about 75 fewer than initial projections
Advertisement

Related Content

FDA PDUFA Performance Hampered By Inadequate Staffing – OND’s Jenkins
FDA PDUFA Performance Hampered By Inadequate Staffing – OND’s Jenkins
IND User Fees May Be Ready For “Prime Time” In PDUFA IV Negotiations
IND User Fees May Be Ready For “Prime Time” In PDUFA IV Negotiations
PDUFA IT Goals Include Security, CDER-CBER Integration In Short-Term
PDUFA IT Goals Include Security, CDER-CBER Integration In Short-Term
PDUFA IT Goals Include Security, CDER-CBER Integration In Short-Term
October User Fee Lineup Includes 7 NMEs; Many Expect “Approvable” Action
October User Fee Lineup Includes 7 NMEs; Many Expect “Approvable” Action
Advertisement
UsernamePublicRestriction

Register

PS042607

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel